Floatz logo

Nivolumab

Recurrent Anaplastic Large Cell Lymphoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

51 Active assets in the Recurrent Anaplastic Large Cell Lymphoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Seagen Inc.
Phase 4BBB
Crizotinib
Pfizer
Phase 4BBB
Inno-206
City of Hope Medical Center
Phase 4BBB
Brentuximab Vedotin
Seagen Inc.
Phase 3BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BBB

View all 50 →

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →